ARCT - Arcturus Therapeutics Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.80
+0.05 (+0.51%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.75
Open9.90
Bid7.15 x 1200
Ask22.00 x 800
Day's Range9.38 - 9.90
52 Week Range4.78 - 15.19
Volume42,425
Avg. Volume21,935
Market Cap105.29M
Beta2.86
PE Ratio (TTM)N/A
EPS (TTM)-3.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Arcturus Therapeutics Expands Management Team

    Arcturus Appoints Senior VP of Business Development & Alliance Management and VP of Translational Biology. SAN DIEGO, Sept. 21, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today ...

  • GlobeNewswire26 days ago

    Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor

    SAN DIEGO, Aug. 29, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that at the Company’ s Annual General Meeting of Shareholders on August 24, 2018, shareholders of ...

  • GlobeNewswire27 days ago

    Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer

    Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, today announced that it has appointed Andrew Sassine as Interim Chief Financial Officer (CFO), effective August 24, 2018. Mr. Sassine has served on Arcturus’ Board of Directors since May 2018 and will continue to serve on Arcturus’ Board of Directors. “In a short period of time since joining our Board in May, Andy has made significant contributions toward the financial stewardship of Arcturus – I am very pleased to have him join our leadership team in this interim, but important role,” said Joseph Payne, President & CEO of Arcturus Therapeutics.

  • GlobeNewswire28 days ago

    Arcturus Therapeutics to Present at Three Investor Conferences in September

    SAN DIEGO, Aug. 27, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that Joseph E. Payne will present at the upcoming conferences, including the B. Riley FBR Annual ...

  • GlobeNewswire2 months ago

    Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics

    Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, today announced the achievement of key milestones as part of its agreement with Cystic Fibrosis Foundation (CF Foundation) Therapeutics, Inc. The completion of these success-driven milestones has triggered an undisclosed payment to Arcturus from the CF Foundation to advance LUNAR-CF, an mRNA therapeutic program to treat cystic fibrosis. Arcturus recently presented preclinical data at the Cystic Fibrosis Foundation Research Conference during June 18-21 in Jackson Hole, Wyoming. Given the success of the ongoing program, Arcturus and the CF Foundation have agreed to expand the scope of activities included in the research agreement and have amended the milestone criteria to further define the plan to advance the program into clinical development.

  • GlobeNewswire2 months ago

    Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018

    To approve the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 and to authorize the board of directors of the Company (the “Board”) to determine its compensation. To approve an amended and restated Compensation Policy for the Company’s Office Holders. To approve the re-election as directors of the Board, until the next annual general meeting of the Company, of each of the following currently serving directors: Mr. Joseph Payne, Dr. Peter Farrell, Mr. Andy Sassine, Dr. Magda Marquet and Mr. James Barlow.

  • GlobeNewswire3 months ago

    Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

    All Four Proposals Approved by Shareholders. SAN DIEGO, July 09, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that at its Extraordinary General Meeting of Shareholders ...

  • ACCESSWIRE5 months ago

    Blog Exposure - Arcturus Initiates Lawsuit against Former CEO Joseph Payne for Misconduct and Violations of Federal Disclosure

    Stock Monitor: PLx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Arcturus Therapeutics Ltd (NASDAQ: ARCT ) ("Arcturus"). ...